FBXW7 and gastrointestinal stromal tumor: Critically, combining imatinib with agents targeting these specific ubiquitination nodes (deubiquitinase inhibitors, ferroptosis inducers like RSL3, or FBXW7 modulators) is a rational, multi-pronged strategy to overcome resistance and improve GIST treatment outcomes (68, 71, 82).